1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Hanmi Science Co., Ltd

Hanmi Science Co., Ltd

KKRX:008930
42,900.00
KRW
-700.00
(-1.61%)
2,226.23EPS
13.53P/E
2.04TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,077.04
7,685.71
11,431.24
9,737.71
9,765.64
10,308.72
11,664.81
12,251.37
13,579.72
15,265.44
18,362.8
18,963.69
20,038.55
20,537.06
Basic EPS, GAAP
134.05
307.54
2,629.06
116.18
450.15
262.37
439.12
322.95
613.73
1,010
1,694
878
1,748
2,227.76
Free Cash Flow per Basic Share
-20.99
48.95
598.24
1,031.83
-566.14
22.18
157.97
169.57
164
16.19
389.66
1,054.22
394.95
386.6
Dividend per Share
- -
- -
- -
404.27
- -
177.55
177.64
181.23
184.86
192.5
196.19
300.3
199.99
- -
Book Value per Share
6,307.47
6,434.14
8,768.84
9,395.94
9,881.15
9,703.45
9,594.72
9,790.1
10,261.19
10,871.82
11,621.38
12,418.89
14,204.7
15,669.34
Tangible Book Value per Share
6,249.39
6,354.1
8,660.84
9,272.57
9,694.75
9,537.33
9,440.01
9,659.1
10,148.47
10,584.91
10,630.61
11,613.44
13,972.17
15,429.33
Basic Weighted Avg Shares
71
69
68
68
67
69
70
70
70
69
68
68
68
68
Sales/Revenue/Turnover
219,863
532,605
776,215
665,285
652,324
707,995
816,619
857,383
950,165
1,046,054
1,247,906
1,283,432
1,356,958
1,391,246
Operating Margin (%)
2.86
1.69
18.89
2.26
2.14
1.55
1.98
2.93
3.03
2.69
4.57
2.96
4.2
3.61
Depreciation Expense
1,079
1,367
2,032
3,205
4,684
4,606
6,375
6,208
5,257
5,478
8,732
9,711
9,481
9,331
Net Income, GAAP
9,578
21,312
178,521
7,938
30,069
18,020
30,742
22,601
42,942
69,210
115,122
59,422
118,370
150,915
Effective Tax Rate (%)
8.15
- -
24.08
58.02
7.72
4.24
13.23
24.59
12.59
5.66
11.81
10.15
11.5
14.64
Profit Margin (%)
4.36
4
23
1.19
4.61
2.55
3.76
2.64
4.52
6.62
9.23
4.63
8.72
10.85
Working Capital
-9,778
-45,219
93,283
25,279
16,668
17,235
-11,109
-4,386
1,564
-102,378
-121,302
-140,863
-57,775
-40,132
LT Debt
- -
- -
- -
- -
- -
- -
298
5,275
201
6,483
10,769
1,009
579
496
Total Equity
409,066
417,712
584,250
647,564
665,152
653,094
645,687
658,734
690,295
724,748
787,472
838,704
959,193
1,061,036
Return on Invested Capital (%)
2.45
- -
28.33
1.76
5.19
3.66
4.82
3.48
7.01
7.58
11.32
8.58
10.9
12.36
Return on Capital (%)
2.58
- -
32.66
1.31
4.47
2.8
4.73
3.41
6.11
8.71
12.87
7.03
11.52
13.67
Return on Common Equity (%)
2.39
5.17
35.71
1.29
4.59
2.73
4.73
3.47
6.37
9.78
15.23
7.3
13.13
15.6

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
213,952
187,587
183,456
LT Borrowings
- -
- -
- -
LT Finance Leases
579
616
496
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
2,454,622
2,512,178
2,041,568

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
425,770
392,065
376,946
Cash, Cash Equivalents & STI
128,173
116,026
98,924
Accounts Receivable, Net
104,389
107,263
116,082
Inventories
122,542
119,548
127,508
Total Current Liabilities
483,545
448,423
417,077
Payables & Accruals
- -
- -
- -
ST Debt
213,952
187,587
183,456
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.19%
7.86%
14.37%
Free Cash Flow
274.96%
460.09%
-62.51%
Net Income, GAAP
45.56%
53.67%
99.2%
Sales/Revenue/Turnover
6.14%
9.76%
5.73%
Total Cash Common Dividend
- -
4.82%
-33.37%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
346,408
309,096
338,039
331,710
1,283,432
2025
352,044
338,269
362,098
285,670
1,356,958
2026
375,621
367,856
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
469
308
263
-161.99
878
2025
370
425
476.74
476.41
1,748
2026
630.46
644
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
100.13
- -
300.3
2025
- -
- -
- -
- -
199.99
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Kyo Kim
Full Time Employees
489
Sector
Distribution services
Industry
Medical distributors
Address
14, Wiryeseong-daero Hwaseong-si GY South Korea 05545
IPO Date
Jun 20, 1988
Website
hanmiscience.co.kr
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Hanmi Science Co., Ltd. (008930.KS) manufactures and sells pharmaceutical products through its subsidiaries in Korea and internationally; it develops drugs focused on diabetes and anti-cancer treatments, children's and adults' bowel preparation and cold medicines, and cephalosporin antibiotics, while also offering general foods, health functional foods, soy milk, medical equipment, and automated drug management systems sold via online and offline pharmacies. Founded in 1973 and headquartered at 14 Wiryeseong-daero, Songpa-gu, Seoul, South Korea, the company operates primarily in the healthcare sector with 444 employees and targets medical, consumer, and institutional customers across domestic and global markets. In recent developments, Hanmi Science, as part of the Hanmi Pharmaceutical Group, engages in strategic collaborations such as the October 2024 partnership and investment with MEDiC Life Sciences for cancer biomarker discovery to enhance oncology programs, alongside expansions into the Middle East and Latin America through alliances like the September 2025 agreement with Tabuk Pharmaceuticals, and ongoing financial arrangements including the amended September 2025 loan extension with Aptose Biosciences.